Imperative Care’s Zoom 88 Large Distal Platform Support, a catheter-based treatment that enhances reperfusion in poststroke patients, has been approved by the FDA. This approval broadens the company’s entire stroke system, known as the Zoom Stroke Solution. The newly introduced function improves thrombectomy stability and control by retaining 0.88″ intracranial access and allowing clinicians to treat more proximal or tandem occlusions. Zoom Aspiration Catheters, Zoom POD and Pump, and the current Zoom 88 LDP and Zoom RDL Access Platform are all part of the Zoom Stroke Solution. The technique has proven effective in treating patients with middle cerebral artery occlusions, achieving high rates of reperfusion. The median time from access to the first aspiration attempt was 10 minutes, and the median time from access to the second aspiration attempt was 15 minutes.

To know more: About the original article click here.